[Current position of beta-adrenergic blockers in the management of arterial hypertension].
Discussed is the actual controversy concerning the role of P-adrenergic blocking agents in the treatment of arterial hypertension. The author argues that these drugs are not suitable for elderly hypertensive patients, particularly in primary stroke prevention. The diabetogenic and atherogenic potential of these agents is marginal, and there are no marked differences between the available P blockers (atenolol has possibly some slight disadvantages). However, for the time being these drugs remain in the first line antihypertensive armamentarium for the younger hypertensive patients; for compelling indications or intolerance of other antihypertensives should be prescribed to any patient, as Croatian Society of Hypertension concluded in 1999.
Rumboldt
Zvonko
Z
Katedra za internu medicinu, Medicinski fakultet Mostar.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*
D000319:Adrenergic beta-Antagonists